Andrew Gottesdiener
Partner @ Venrock
New York, United States
Andrew Gottesdiener is a seed investor at Venrock in New York focused on Health Care and Biotechnology. Andrew Gottesdiener is based out of New York, New York, and is the Partner of Venrock and Board of Director at Korsana Biosciences. Andrew Gottesdiener attended Washington University in St. Louis.
- Total investments:
- 3
- Last investment:
- Lead investor:
- 33%
Last updated:
For AI agents: llms.txt
Industries Andrew Gottesdiener invests in
Stages Andrew Gottesdiener invests in
Countries Andrew Gottesdiener invests in
Contacts
| Type | Contact | Validation |
|---|---|---|
| Work email | ||
| Personal email | ||
| Work phone | ||
| Personal phone | ||
| Socials |
Investment Focus
Industry
- Health Care 2 (67%)
- Biotechnology 2 (67%)
- Medical 1 (33%)
- Biopharma 1 (33%)
- Life Science 1 (33%)
Stage
- Seed 1 (33%)
- Series C 1 (33%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Lycia Therapeutics
|
Lycia Therapeutics is a biotechnology company that focuses on developing technology that utilizes lysosome-targeting chimeras. The company was founded by Carolyn R. Bertozzi in 2019 and is based in San Diego, California, USA. | $75M / Series D / Jun 25, 2026 | |
|
Lycia Therapeutics
|
Lycia Therapeutics is a biotechnology company that focuses on developing technology that utilizes lysosome-targeting chimeras. The company was founded by Carolyn R. Bertozzi in 2019 and is based in San Diego, California, USA. | $106.6M / Series C / May 13, 2024 | |
Korsana Biosciences
|
Korsana Biosciences develops THETA-enabled antibody therapies for neurodegenerative diseases. The company focuses on shuttled monoclonal antibodies that cross the blood-brain barrier to reach central nervous system targets. Its lead program, KRSA-028, is an investigational anti-amyloid beta antibody for Alzheimer’s disease that uses a transferrinreceptor-based shuttle and Fc engineering to improve brain delivery and dosing. Korsana is also advancing additional THETA-based programs for undisclosed neurodegenerative indications. | $25M / Seed / Jan 01, 2024 |
Co-Investors
About Venrock
Venrock continues a tradition of partnering with entrepreneurs to establish successful, enduring companies. With a primary focus on technology and healthcare, portfolio companies have included Apple Computer, Athenahealth, Centocor, Check Point Software, DoubleClick, Endeca, Gilead Sciences, Idec Pharma, Imperva, Illumina, Intel, Nest, SlideShare,and Tudou.
Venrock Contacts
| Name | Phone | Socials | |
|---|---|---|---|
|
Andrew Gottesdiener
Partner
|
|||
Anthony Evnin
Partner Emeritus
|
|||
Bryan Roberts
Partner
|
|||
Mariana Mihalusova
Vice President
|
|||
Mike Tyrrell
General Partner
|
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Recommended lists
FAQ
What does Andrew Gottesdiener invest in?
Andrew Gottesdiener invests primarily in Health Care, Biotechnology and Medical startups, most often at Seed and Series C stage. Most of the 3 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Andrew Gottesdiener?
Public channels for Andrew Gottesdiener include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
When did Andrew Gottesdiener last invest?
The most recent investment recorded for Andrew Gottesdiener closed in Jun 2026. Shizune tracks 3 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
